Amneal Pharmaceuticals (AMRX) Other Non-Current Assets (2017 - 2026)

Amneal Pharmaceuticals' Other Non-Current Assets history runs 10 years deep, the most recent figure standing at $54.9 million for Q1 2026.

• On a quarterly basis, Other Non-Current Assets rose 20.83% year-over-year to $54.9 million in Q1 2026; TTM through Mar 2026 was $54.9 million, a 20.83% increase from a year earlier, with the FY2025 full-year figure at $57.8 million, down 3.87% from the prior year.
• Other Non-Current Assets eased to $54.9 million in Q1 2026 per AMRX's latest filing, from $57.8 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $108.3 million in Q3 2022 and bottomed at $36.3 million in Q3 2024.
• The 5-year median for Other Non-Current Assets is $63.9 million (2022), against an average of $68.8 million.
• Across the five-year window, Other Non-Current Assets surged 454.39% in 2022 and plunged 59.26% in 2024, its largest moves.
• Year by year, Other Non-Current Assets stood at $103.2 million in 2022, then sank by 46.21% to $55.5 million in 2023, then climbed by 8.31% to $60.1 million in 2024, then retreated by 3.87% to $57.8 million in 2025, then declined by 5.06% to $54.9 million in 2026.
• Per Business Quant, the three latest AMRX Other Non-Current Assets figures stand at $54.9 million (Q1 2026), $57.8 million (Q4 2025), and $39.5 million (Q3 2025).